stockrow
Friday 6 November 2026
Export STTK’s income statement to Excel — free account
Shattuck Labs, Inc.
STTK Healthcare Biotechnology
Shattuck Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 82.5% from fiscal 2024.
- Revenue
- −10.3%
- EPS
- +50.0%
- Free cash flow
- +1.01%
Quarter to June 2026, against a year earlier
4.59
0.10
+2.23%
Follow STTK
Alert me
Shattuck Labs, Inc. (STTK) P/E ratio
Shattuck Labs, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MNPR Monopar Therapeutics Inc. compare | n/m |
| STTK Shattuck Labs, Inc. | n/m |
| GYRE Gyre Therapeutics, Inc. compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| ARVN Arvinas, Inc. compare | n/m |
| CTMX CytomX Therapeutics, Inc. compare | n/m |
| MDXG MiMedx Group, Inc compare | n/m |
| ETRA Electra Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)